Revolution Medicines, Inc. (RVMD) Stock Analysis

The estimated fair value of Revolution Medicines, Inc. (RVMD) is $116.36, according to Convex's multi-method conviction framework. Fair value is our estimate of what a share is intrinsically worth based on the company's cash flows, earnings, and balance sheet, not simply its current market price, which can diverge from fundamentals in the short term. We arrive at this figure by blending ev_revenue, analyst_target, each of which values the business from a different angle to reduce the risk of relying on any single model. We then apply a quality premium of 0%, which adjusts the blended estimate based on the company's profitability, balance-sheet strength, and competitive position. The confidence level of this estimate is moderate, reflecting how much analyst coverage, data consistency, and business predictability support the calculation. A wider gap between fair value and the current price generally signals more potential upside or downside, but this estimate should be read alongside the company's business risk and your own investment horizon.

RVMD currently has a SPECULATIVE_AVOID rating from Convex's conviction engine, with a conviction score of 1 out of 10. This score summarizes how strongly the underlying data, including valuation, quality, momentum, and risk-reward, supports the rating: higher scores indicate stronger alignment across these factors, while lower scores reflect more mixed or uncertain signals across the same categories. Pre-profit company with limited upside (-35%) and/or quality concerns (grade D). A rating like this is not a guarantee of future performance; it is a snapshot of how the stock scores today against our framework, and it can change as new earnings, price action, or analyst estimates come in over time. Do not initiate a position. Wait for significant price improvement or catalysts.. Investors should treat this rating as one input among several, combining it with their own research into the company's business model and competitive position, and weighing it carefully against their personal risk tolerance and investment time horizon before making any final decision.

Revolution Medicines, Inc. has a quality grade of D, based on a score of 37 out of 120 points across profitability, balance-sheet strength, and capital efficiency, which Convex rates overall as PRE-PROFIT QUALITY: Grade D (37/100). Three metrics drive this grade. Return on equity (ROE) of —% measures how much profit the company generates for every dollar of shareholder capital, with higher figures generally showing management using equity productively. The ROIC-WACC spread of —% compares the return on invested capital against the company's cost of capital: a positive spread means the business creates value by earning more than it costs to fund operations, while a negative spread suggests capital is being destroyed. The debt-to-equity (D/E) ratio of 0.1x shows how much debt the company carries relative to shareholder equity, with lower ratios indicating less balance-sheet risk. Together these metrics show whether the company is fundamentally sound enough to withstand downturns and fund future growth.

RVMD is classified as a "cyclical" in Convex's conviction framework. This classification groups stocks by business stage and growth profile, such as mature compounders, cyclical businesses, high-growth names, or turnaround situations, because the right valuation method and the risks that matter most differ significantly between these categories. Low dividend (reinvesting): 0.0%, Mature growth: 0.0%, High revenue volatility: 62.0% std dev, High beta (cyclical behavior): 1.38, Consistent FCF: 3/3 years positive Knowing a stock's classification helps set realistic expectations: a high-growth stock is typically judged on revenue expansion and its path to profitability rather than current earnings multiples, while a mature compounder is judged more on steady cash flow, dividends, and capital returns to shareholders over time. This classification also determines which fair-value methods and quality benchmarks Convex applies when scoring the stock, since a one-size-fits-all valuation approach would misprice companies with very different growth trajectories, cash flow profiles, competitive dynamics, and capital needs relative to their industry peers and broader sector.

22 Wall Street analysts currently cover RVMD, and their consensus price target is $195.00, implying +8.1% from the current share price. Analyst price targets are professional estimates of where a stock's price could trade over the next twelve months, based on each analyst's own models for earnings, growth, and valuation multiples; they are informed opinions, not guarantees. Individual targets vary, ranging from a low of $144.00 to a high of $235.00, which reflects genuine disagreement among analysts about the company's outlook, risks, and appropriate valuation. The consensus recommendation across these analysts is "Strong Buy," summarizing whether the broader sell-side view leans toward buying, holding, or selling the stock. Our model is more cautious than Wall Street. Because analyst targets can lag real-time news and sometimes reflect optimism tied to investment-banking relationships, they are best used as one data point alongside independent fundamental research rather than a standalone signal.

The risk/reward asymmetry ratio for RVMD is -0.16:1, which Convex rates as Unfavorable. This ratio compares the potential upside in a bullish scenario against the potential downside in a bearish scenario, so a ratio above 1:1 means the potential gain outweighs the potential loss if both scenarios were equally likely, while a ratio below 1:1 signals the opposite. Risk/reward ratio of -0.2:1 (UNFAVORABLE). Pre-profit valuations carry wider ranges. The expected return, a probability-weighted average across bull, base, and bear scenarios, is -39.4%, giving a single blended estimate of what an investor might reasonably expect. In the bull case, upside is projected at +-9.7%, while in the bear case, downside risk is projected at -61.3%. Comparing these ranges helps investors judge whether the potential reward justifies the risk being taken, though actual outcomes depend on execution, macro conditions, and sector sentiment that no model can fully predict.

RVMD is currently in a bullish trend, based on Convex's technical analysis of recent price action, moving averages, and momentum indicators. Price ($180.39) is 65.2% above SMA 200 ($109.18). Bullish trend confirmed. A trend reflects the recent direction of a stock's price movement and trading momentum; it does not predict future performance, since trends can reverse quickly on news, earnings, or shifts in broader market sentiment. To quantify this, Convex assigns a technical score of — out of 100, which aggregates signals like moving-average crossovers, relative strength, and volume patterns into a single measure of short-term momentum, where higher scores indicate stronger bullish alignment and lower scores suggest weakening or bearish momentum. Technical analysis like this is typically most useful for timing entries and exits around a position an investor has already decided to take based on fundamentals, rather than as a standalone reason to buy or sell a stock.